All News

It’s hardly news that biopharmaceutical companies today face increasing pressure to innovate, produce, improve efficiency and quality.

The innovative pharmaceutical industry is under attack from critics around the world for failing to develop new antibiotics to treat emerging infections.

Pharm Exec’s Brand of the Year award is itself a brand with staying power - our first recipient was Merck’s Gardasil papillomavirus vaccine.

Europe’s pharma industry association EFPIA has launched its ”Manifesto for an Integrated Life Sciences Strategy in Europe”.

As expected, the PFE/AZ saga has just begun to play out, and as we listen to the music of mega-mergers once again.

Diabetes, it can be said, is one of the unpleasant side-effects of being human.

The Pfizer-AstraZeneca courtship raises many fascinating questions about the future shape of the international pharmaceutical industry.

A CCG had denied funding for oocyte preservation for a woman with Crohn’s disease before she had bone marrow transplant and chemotherapy.

In our final Q&A installment previewing next week’s iPharma2014 digital forum.

Gilead’s hepatitis C treatment Sovaldi will top the list of biggest selling drugs in 2020, according to UK market intelligence company, Evaluate.

More than half a century ago, way before anyone had dreamt up the notion of digital disruption.

The confirmation of Pfizer’s bid for an outright acquisition of AstraZeneca has drawn mixed reactions from the UK.

The dizzying flurry of press releases from both Pfizer Inc. and AstraZeneca over a possible PFE acquisition of AZN have Rx experts on both sides of the Atlantic buzzing.

The pancreatic cancer market is set to climb from $855.8 million in 2012 to approximately $1.21 billion by 2019 (a CAGR of 5.1%), says a report from GBI Research.

New data maintenance guidelines have sparked a flurry of activity in Europe.

The Incremental Cost Effectiveness Ratio (ICER) thresholds used by agencies such as the UK’s National Institute for Health and Care Excellence (NICE).

Gilead Silences has cleaned up on their new $1,000 Hepatitis C pill Sovaldi (84,000 per treatment), hauling in a record-breaking $2.3 billion in its first full quarter on the market.

The recently released Medicare data on payments to individual doctors doesn’t provide specifics on prescription drug outlays,

Because Tuesday the stock market was buzzing following the news that Novartis is to acquire GSK’s cancer drugs business, while selling its vaccines division to GSK.

With all of the activity in CRO M&As the past three years, it’s slightly amazing that it continues - and that analysts don’t see it slowing down.

The Department of Veterans Affairs and other California panels’ solution to the new and extremely costly hepatitis (Hep) C drugs (Sovaldi and Olysio) is to reserve them for the patients with advanced liver diseases, including those awaiting transplants.

In the midst of the hue and cry last week over the public release of individual Medicare payments to physicians, I was surprised to read that one of Medicare’s most costly medical services is - ophthalmology.

Overall, last year can be considered quite a successful one in terms of new product approvals.

Health IT is going through an era of both expansion and convergence, in which the universe of available information is growing exponentially.

We spend a lot of time focusing on what our advertising says to physicians, what our reps say to physicians, and what our websites and various other channels communicate to patients.

The European Medicines Agency is determined to minimize opposition to its next moves on releasing clinical trial data.

Pharma has operated the same way for 100 years, but the US healthcare model has changed completely in the last 30 years, for payers, pharmacists, hospitals, and even at the clinician level.

If the American public could shed girth as quickly as many medical journals have in recent years, we’d all be a lot healthier.

An industry and academic data-sharing project went live on Tuesday, nearly a year after the platform was expected to launch.

An industry and academic data-sharing project went live on Tuesday, nearly a year after the platform was expected to launch.